INVESTIGATION OF THE ACTIVITY OF 1.3-DIAZINONE-4 NEW DERIVATIVES AND THEIR NON-CYCLIC PRECURSORS IN RESPECT OF ESCHERICHIA COLI

In various countries of the world, for at least last fifteen years, in the structure of nosocomial infections the leading position has been occupied by gram-negative pathogens, Escherichia coli in particular. The data of the World Health Organization testify the increasing resistance of this pathogen to antibiotics, which determines the relevance of creating and developing new antimicrobial agents. Primary screening of new 1.3-diazinon-4 derivatives and their non-cyclic precursors made it possible to identify the leader compounds capable of active suppressing the growth of E. coli and promising for the further study. The aim of the study is to investigate the activity of the compounds under laboratory ciphers of PYaTs4, PYaTs6, PYaTs7, PJTd8, PYaTd9, PYaTd15 with respect to Escherichia coli. Materials and methods. The study of the activity of the compounds was carried out on the basis of collection and freshly isolated strains from patients with different pathologies. Before the inoculation all the strains were identified by means of the BIOMIC V3 software complex (Giles Scientific, USA) to confirm their belonging to the genus and species. The strains used in the work were previously tested for susceptibility to antibacterial drugs by the disk method to assess the presence or absence of resistance. The activity of the new compounds was studied by the serial dilution method. Results and discussion. The investigation of the sensitivity of the strains by the disk method to antibacterial drugs used in the etiotropic therapy of infections caused by Escherichia coli revealed microorganisms with multiple drug resistance. The analysis of the inoculation of the strains showed that all the studied compounds have the ability to suppress the growth of E. coli being both collectively and freshly isolated from patients with various pathologies. Conclusion. The substances under the laboratory ciphers of PYaTd8 and PYaTs4 are the most active in respect to the studied strains. At the same time, the MIC50 (minimum inhibitory concentration) of all the compounds does not exceed 10–20 μg / ml, which makes them promising for the further study.

1. Reshedko GK, Tschebnikov AG, Morozov MV, Reshedko LA. Escherichia coli kak vozbuditel’ nozokomial’nyh infekcij v ORIT [Escherichia coli as a Nosocomial Pathogen in ICUs]. Clinical Microbiology and Antimicrobial Chemotherapy. 2011;13(4):314–21. Russian.

2. Garnica M, Maiolino A, Nucci M. Factors associated with bacteremia due to multidrug-resistant Gram-negative bacilli in hematopoietic stem cell transplant recipients. Braz. J. Med. Biol. Res. 2009 Mar;42(3):289–93. DOI: 10.1590/S0100-879X2009000300010

3. Gikas A, Pediaditis J, Papadakis JA, Starakis J, Levidiotou S, Nikolaides P, Kioumis G, Maltezos E, Lazanas M, Anevlavis E, Roubelaki M, Tselentis Y. Prevalence study of hospital-acquired infections in 14 Greek hospitals: planning from the local to the national surveillance level. J. Hosp. Infect. 2002 Apr;50(4):269–75. DOI: 10.1053/ jhin.2002.1181

4. Merchant S, Gast C, Nathwani D, Lee M, Quintana A, Ketter N, Friedland I, Ingham M. Hospital resource utilization with doripenem versus imipenem in the treatment of ventilator-associated pneumonia. Clin. Ther. 2008 Apr;30(4):717–33. DOI: 10.1016/j.clinthera.2008.04.001

5. Rudnov VA, Belsky DV, Dekhnich AV. Infekcii v ORIT Rossii: rezul’taty nacional’nogo mnogocentrovogo issledovaniya [Infections in Russian ICUs: Results of the Nationalwide Multicenter Study]. Clinical Microbiology and Antimicrobial Chemotherapy. 2011;13(4):294–303. Russian.

6. Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ. Antimicrobial susceptibility among organisms from the Asia, Pacific Rim, Europa and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J. Antimicrob. Chemother. 2007;60:1018–29. DOI:10.1093/jac/dkm310

7. Van der Kooi TI, Manniën J, Wille JC, van Benthem BH. Prevalence of nosocomial infections in The Nether-lands, 2007-2008: results of the first four national studies. J. Hosp. Infect. 2010;75(3):168–72. DOI: 10.1016/j. jhin.2009.11.020

8. Senbayrak S, Inan A, Cevan S, Ozaydin A, Cobanoglu N, Ozyurek S, Aksaray S. Gram-negative baciili causing infections in an intensive care unit of a tertiary care hospital in Istambul, Turkey. J. Inf. Dev. Coun. 2014;8(5):597– 604. DOI: 10.3855/jidc.4277

9. Ryabkova EL, Ivanchik NV, Sukhorukova MV, Schebnikov AG, Reshedko GK. Rezistentnost’ nozokomial’nyh shtammov Escherichia coli v stacionarah Rossii [Antimicrobial Resistance of Nosocomial Strains of Escherichia coli in Russian Hospitals]. Clinical Microbiology and Antimicrobial Chemotherapy. 2009;11(2):161–9. Russian.

10. Sukhorukova MV, Edelstein MV, Skleenova EYu, Ivanchik NV, Mikotina AV, Dekhnich AV, Kozlov RS. Antibiotikorezistentnost’ nozokomial’nyh shtammov Enterobacteriaceae v stacionarah Rossii: rezul’taty mnogocentrovogo epidemiologicheskogo issledovaniya «MARAFON» 2013–2014 [Antimicrobial resistance of nosocomial Enterobacteriaceae isolates in Russia: results of multicenter epidemiological study “MARATHON” 2013–2014]. Clinical Microbiology and Antimicrobial Chemotherapy. 2017;19(1):48–56. Russian.

11. Kozlov RS, Sukhorukova MV, Sidorenko SV, Edelstein MV, Skleenova Е.Yu., Ivanchik NV, Mikotina АV, Gostev VV, Lazareva IV, Kalinogorskaya OS, Volkova MO, Dekhnich АV. CHuvstvitel’nost’ osnovnyh vozbuditelej bakterial’nyh infekcij k ceftarolinu v Rossijskoj Federacii [In vitro Ceftaroline Activity against Major Bacterial Pathogens n Russia: Results of Multicenter Study]. Clinical Microbiology and Antimicrobial Chemotherapy. 2015;17(3):217–26. Russian.

12. Kozlov RS, Golub AV, Dekhnich AV, Sukhorukova MV. Antibiotikorezistentnost’ gramotricatel’nyh vozbuditelej oslozhnennyh intraabdominal’nyh infekcij v Rossii [Antimicrobial Resistance of Gram-negative Microorganisms Causing Complicated Intra-abdominal Infections in Russia]. Clinical Microbiology and Antimicrobial Chemotherapy. 2015;17(3):227–34. Russian.

13. Arslan H, Azap OK, Ergonul O, Timurkaynak F, Urinary Tract Infection Study G. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J. Antimicrob. Chemother. 2005 Nov;56(5):914–8. DOI: 10.1093/jac/dki344

14. Chérif T, Saidani M, Decré D, Boutiba-Ben Boubaker I, Arlet G. Cooccurrence of Multiple AmpC β-Lactamases in Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis in Tunisia. Antimicrob. Agents Chemother. 2015 Oct 12;60(1):44–51. DOI: 10.1128/AAC.00828-15

15. Gupta K, Sahm DF, Mayfield D, Stamm WE. Antimicrobial resistance among uropathogens that cause community acquired urinary tract infections in women: a nationwide analysis. Clin. Infect. Dis. 2001 Jul;33(1):89–94. DOI: 10.1086/320880

16. Karlowsky JA, Kelly LJ, Thornsberry C, Jones ME, Sahm DF. Trends in antimicrobial resistance among urinary tract infectionisolates of Escherichia coli from female outpatients in the United States. Antimicrob. Agents. Chemother. 2002 Aug;46(8):2540–5. DOI: 10.1128/AAC.46.8.2540–2545.2002

17. Lockhart SR, Abramson MA, Beekman SE, Gallagher G, Riedel S, Diekema DJ, Quinn JP, Doern GV. Antimicrobial resistance among gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004. J. Clin. Microbiol. 2007;45(10):3352–9. DOI: 10.1128/JCM.01284-07

18. Luzzaro F, Gesu G, Endimiani A, Ortisi G, Malandrin S, Pagani L, Rossolini GM. Performance in detection and reporting beta-lactam resistance phenotypes in Enterobacteriaceae: a nationwide proficiency study in Italian laboratories. Diagn. Microbiol. Infect. Dis. 2006 Aug;55(4):311–8. DOI: 10.1016/j.diagmicrobio. 2006.01.017

19. Luzzaro F, Ortisi G, Larosa M, Drago M, Brigante G, Gesu G. Prevalence and epidemiology of microbial pathogens causing bloodstream infections: results of the OASIS multicenter study. Diagn. Microbiol. Infect. Dis. 2011 Apr;69(4):363–9. DOI: 10.1016/j.diagmicrobio.2010.10.016

20. Neuchauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units. J. Americ. Med. Association. 2003;289(7):885–8. DOI: 10.1001/ jama.289.7.885

21. Rafal’skij VV, Strachunskij LS, Krechikova OI, Ejdel’shtejn IA, Ahmetova LI, Babkin PA, Gugucidze EN, Il’ina VN, Kogan MI, Kopylov VV, Malev IV, Petrov SB, Rafal’skaya LV, Furletova NM. Rezistentnost’ vozbuditelej ambulatornyh infekcij mochevyvodyashchih putej po dannym mnogocentrovyh mikrobiologicheskih issledovanij UTIAP-I i UTIAP-II [Resistance of pathogens of outpatient urinary tract infections according to multicenter microbiological studies of UTIAP-I and UTIAP-II]. Urologiia. 2004;2:13–7. Russian.

22. Skepyan EN, Vasilevski IV, Toptun PD. Analiz spektra vozbuditelej infekcij mochevyvodyashchih putej i harakteristika ih chuvstvitel’nosti k protivomikrobnym lekarstvennym sredstvam u detej na ambulatornom etape [Analysis of the spectrum of infections of the urinary tract and the characteristic their sensitivity to antimicrobial drugs the children’s outpatient]. Medicinskaya panorama. 2013;8:35–8. Russian.

23. Palagin IS, Nikiforovskaya EN. Vzglyad na primenenie ceftibutena v terapii vnebol’nichnyh infekcij mochevyh putej v Rossii [Ceftibuten in the Treatment of Community-Acquired Urinary Tract Infections in Russia]. Clinical Microbiology and Antimicrobial Chemotherapy. 2015;17(4):286–90. Russian.

24. Budnik TV. Antibiotikorezistentnost’ v kontekste infekcii mochevyvodyashchih putej [Antibiotic resistance in the context of a urinary tract infection]. [Internet]. [cited 2016 Nov 16]. Available from: http://www.olfa.ua/post/ antibiotikorezistentnost-v-kontekste-infekcii-mochevyvodyashih-putej-br-t-v-budnik. Russian.

25. Reporting protocol: The European Antibiotic Resistance Surveillance Network (EARS-Net). 2013. Version 3. 43 p.

26. Ustojchivost’ k protivomikrobnym preparatam: global’nyj doklad po epidnadzoru 2014: doklad VOZ, 2014 [Antimicrobial resistance: the global surveillance report 2014: WHO report, 2014]. [Internet]. [cited 2014 Dec 12] Available from: http://apps.who.int/iris/bitstream/10665/112642/1/9789241564748_eng.pdf?ua=1. Russian.

27. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. [Internet]. WHO publication, February 2017 [cited 2017 Iul 15] Available from: http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.

28. Kodonidi IP. Molekulyarnoe konstruirovanie N-zameshchennyh proizvodnyh 1,3-diazinona-4 [Molecular design of n-substituted 1,3-diazinone-4 derivatives]. Pharmacy. 2010;1:36–40. Russian.

29. Luzhnova SA, Voronkov AV, Gabitova NM, Suda Billel’. Poisk effektivnyh sinteticheskih soedinenij s vysokoj antimikrobnoj aktivnost’yu [Search for effective synthetic compounds with high antimicrobial activity]. V sbornike: Farmacevticheskie nauki: ot teorii k praktike. Zaochnaya nauchno-prakticheskaya konferenciya s mezhdunarodnym uchastiem. Astrahan’: FGBOU VO «Astrahanskij gosudarstvennyj medicinskij universitet» Minzdrava Rossii, 2016;60–1. Russian.

30. Metodicheskie rekomendacii «Metody bakteriologicheskogo issledovaniya v klinicheskoj mikrobiologii» [Methodical recommendations “Methods of bacteriological research in clinical microbiology”]. [Internet]. 1983 [cited 2014 Mar 12]. Available from: www.libussr.ru/doc_ussr/usr_11426.htm. Russian.

31. Rukovodstvo po provedeniyu doklinicheskih issledovanij lekarstvennyh sredstv [Guidelines for preclinical drug research]. Mironov AN, editor. Moscow: Grif i K, 2012. P. 509–21. Russian.

32. Semina NA, Sidorenko SV, Rezvan SP, Grudinina SA, Strachunskij LS, Stecyuk OU, Kozlov RS, Endel’shtejn MV, Ved’mina EA, Stolyarova LG, Vlasova IV, Sereda ZS. Opredelenie chuvstvitel’nosti mikroorganizmov k antibakterial’nym preparatam [Determination of the sensitivity of microorganisms to antibacterial drugs.]. Metodicheskie ukazaniya MUK 4.2. 1890-04. Federal’nyj centr gossanepidnadzora Minzdrava Rossii. 2004. 91 p. Russian.